Germany reimburses on day one and negotiates afterwards. The benefit assessment that follows sets the price for every year after that.
Germany is the inverse of most markets. A newly licensed medicine is reimbursed from launch, and the price is negotiated after a benefit assessment. That gives immediate revenue and immediate exposure: the assessment determines the negotiated price that follows, and the finding is what a manufacturer defends.
The assessment turns on demonstrated additional benefit against an appropriate comparator. Orphan medicines follow a modified route in which additional benefit is accepted by virtue of the authorisation, which is a materially easier position than arguing the case through a full dossier. An asset without that standing has to win the finding the hard way.
Because Germany's prices are visible and widely referenced by other countries, the outcome does not stay in Germany. A weak finding here propagates through international reference-pricing baskets across Europe.
AXLRx Germany reports cover the route an asset should expect, the comparator it will be assessed against, the precedent set by agents already through the process, and the reference-pricing exposure the resulting price creates elsewhere.
Iptacopan's substantial-benefit finding gave Germany real negotiating leverage over Novartis. Six months on, no negotiated net price has surfaced in the Lauer-Taxe — the pricing signal this model is built to catch before a launch-sequencing decision locks in the wrong assumption.
Germany's DGHO Onkopedia guideline states plainly that Germany-specific PNH prevalence and incidence figures do not exist. It borrows 16 cases and 1.3 new diagnoses per million annually from British and French registries, and routes all case-finding through just two national centres, Ulm and Essen.
Germany has no confirmed PNH prevalence data of its own. The DGHO's Onkopedia guideline borrows an estimate from British and French registries, and diagnosis funnels through just two national referral centres.
Iptacopan's orphan-drug status let it clear Germany's AMNOG process with an established additional benefit and no comparator dossier at all. Ravulizumab's only PNH-specific G-BA review found no added benefit.
Iptacopan's orphan-drug status let it clear AMNOG with an established additional benefit and a substantial quality-of-life finding. Ravulizumab, tested on Germany's only PNH-specific G-BA review to date, found no added benefit at all.
Iptacopan already cleared Germany's AMNOG process with a substantial benefit finding and no comparator dossier. A new entrant without orphan-pathway standing has to win that same finding the hard way, through IQWiG.
Germany has no domestic PNH prevalence count of its own. DGHO's Onkopedia guideline borrows a 16-per-million estimate from British and French registries, and only two national centres, Ulm and Essen, anchor referral.